Optimizing outcomes in patients (pts) with HER2+ metastatic breast cancer (MBC) through continuous inhibition of HER2 activity: A single institution study.
P. Fedele
No relevant relationships to disclose
L. Orlando
No relevant relationships to disclose
P. Schiavone
No relevant relationships to disclose
N. Calvani
No relevant relationships to disclose
A. Marino
No relevant relationships to disclose
A. Nacci
No relevant relationships to disclose
F. Sponziello
No relevant relationships to disclose
E. Mazzoni
No relevant relationships to disclose
P. Rizzo
No relevant relationships to disclose
S. Cinieri
No relevant relationships to disclose